Lv4
566 积分 2024-05-15 加入
Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility
5天前
已完结
Gender difference in the pharmacokinetics and metabolism of VX‐548 in rats
1个月前
已完结
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
3个月前
已完结
Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
3个月前
已完结
Meeting report: DMPK optimisation strategies and quantitative translational PKPD frameworks to predict human PK and efficacious dose of targeted protein degraders
3个月前
已完结
Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy
3个月前
已完结
Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro , and Preclinical Models
3个月前
已完结
Beyond-Rule-of-Five Compounds Are Not Different: In Vitro–In Vivo Extrapolation of Female CD-1 Mouse Clearance Based on Merck Healthcare KGaA Compound Set
3个月前
已完结
Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space
3个月前
已完结
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
3个月前
已完结
皖公网安备34019202002308
